Cargando…

Predictors of early death in a cohort of Ethiopian patients treated with HAART

BACKGROUND: HAART has improved the survival of HIV infected patients. However, compared to patients in high-income countries, patients in resource-poor countries have higher mortality rates. Our objective was to identify independent risk factors for death in Ethiopian patients treated with HAART. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerene, Degu, Endale, Aschalew, Hailu, Yewubnesh, Lindtjørn, Bernt
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569839/
https://www.ncbi.nlm.nih.gov/pubmed/16948852
http://dx.doi.org/10.1186/1471-2334-6-136
_version_ 1782130218761191424
author Jerene, Degu
Endale, Aschalew
Hailu, Yewubnesh
Lindtjørn, Bernt
author_facet Jerene, Degu
Endale, Aschalew
Hailu, Yewubnesh
Lindtjørn, Bernt
author_sort Jerene, Degu
collection PubMed
description BACKGROUND: HAART has improved the survival of HIV infected patients. However, compared to patients in high-income countries, patients in resource-poor countries have higher mortality rates. Our objective was to identify independent risk factors for death in Ethiopian patients treated with HAART. METHODS: In a district hospital in Ethiopia, we treated adult HIV infected patients with HAART based on clinical and total lymphocyte count (TLC) criteria. We measured body weight and complete blood cell count at baseline, 4 weeks later, then repeated weight every month and complete blood cell count every 12 weeks. Time to death was the main outcome variable. We used the Kaplan Meier and Cox regression survival analyses to identify prognostic markers. Also, we calculated mortality rates for the different phases of the follow-up. RESULTS: Out of 162 recruited, 152 treatment-naïve patients contributed 144.1 person-years of observation (PYO). 86 (57%) of them were men and their median age was 32 years. 24 patients died, making the overall mortality rate 16.7 per 100 PYO. The highest death rate occurred in the first month of treatment. Compared to the first month, mortality declined by 9-fold after the 18(th )week of follow-up. Being in WHO clinical stage IV and having TLC<= 750/mcL were independent predictors of death. Haemoglobin (HGB) <= 10 g/dl and TLC<= 1200/mcL at baseline were not associated with increased mortality. Body mass index (BMI) <= 18.5 kg/m2 at baseline was associated with death in univariate analysis. Weight loss was seen in about a third of patients who survived up to the fourth week, and it was associated with increased death. Decline in TLC, HGB and BMI was associated with death in univariate analysis only. CONCLUSION: The high mortality rate seen in this cohort was associated with advanced disease stage and very low TLC at presentation. Patients should be identified and treated before they progress to advanced stages. The underlying causes for early death in patients presenting at late stages should be investigated.
format Text
id pubmed-1569839
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15698392006-09-16 Predictors of early death in a cohort of Ethiopian patients treated with HAART Jerene, Degu Endale, Aschalew Hailu, Yewubnesh Lindtjørn, Bernt BMC Infect Dis Research Article BACKGROUND: HAART has improved the survival of HIV infected patients. However, compared to patients in high-income countries, patients in resource-poor countries have higher mortality rates. Our objective was to identify independent risk factors for death in Ethiopian patients treated with HAART. METHODS: In a district hospital in Ethiopia, we treated adult HIV infected patients with HAART based on clinical and total lymphocyte count (TLC) criteria. We measured body weight and complete blood cell count at baseline, 4 weeks later, then repeated weight every month and complete blood cell count every 12 weeks. Time to death was the main outcome variable. We used the Kaplan Meier and Cox regression survival analyses to identify prognostic markers. Also, we calculated mortality rates for the different phases of the follow-up. RESULTS: Out of 162 recruited, 152 treatment-naïve patients contributed 144.1 person-years of observation (PYO). 86 (57%) of them were men and their median age was 32 years. 24 patients died, making the overall mortality rate 16.7 per 100 PYO. The highest death rate occurred in the first month of treatment. Compared to the first month, mortality declined by 9-fold after the 18(th )week of follow-up. Being in WHO clinical stage IV and having TLC<= 750/mcL were independent predictors of death. Haemoglobin (HGB) <= 10 g/dl and TLC<= 1200/mcL at baseline were not associated with increased mortality. Body mass index (BMI) <= 18.5 kg/m2 at baseline was associated with death in univariate analysis. Weight loss was seen in about a third of patients who survived up to the fourth week, and it was associated with increased death. Decline in TLC, HGB and BMI was associated with death in univariate analysis only. CONCLUSION: The high mortality rate seen in this cohort was associated with advanced disease stage and very low TLC at presentation. Patients should be identified and treated before they progress to advanced stages. The underlying causes for early death in patients presenting at late stages should be investigated. BioMed Central 2006-09-01 /pmc/articles/PMC1569839/ /pubmed/16948852 http://dx.doi.org/10.1186/1471-2334-6-136 Text en Copyright © 2006 Jerene et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jerene, Degu
Endale, Aschalew
Hailu, Yewubnesh
Lindtjørn, Bernt
Predictors of early death in a cohort of Ethiopian patients treated with HAART
title Predictors of early death in a cohort of Ethiopian patients treated with HAART
title_full Predictors of early death in a cohort of Ethiopian patients treated with HAART
title_fullStr Predictors of early death in a cohort of Ethiopian patients treated with HAART
title_full_unstemmed Predictors of early death in a cohort of Ethiopian patients treated with HAART
title_short Predictors of early death in a cohort of Ethiopian patients treated with HAART
title_sort predictors of early death in a cohort of ethiopian patients treated with haart
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569839/
https://www.ncbi.nlm.nih.gov/pubmed/16948852
http://dx.doi.org/10.1186/1471-2334-6-136
work_keys_str_mv AT jerenedegu predictorsofearlydeathinacohortofethiopianpatientstreatedwithhaart
AT endaleaschalew predictorsofearlydeathinacohortofethiopianpatientstreatedwithhaart
AT hailuyewubnesh predictorsofearlydeathinacohortofethiopianpatientstreatedwithhaart
AT lindtjørnbernt predictorsofearlydeathinacohortofethiopianpatientstreatedwithhaart